Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses two ongoing trials for autoimmunity indications in the US and how AlloNK differs from traditional B-cell depletion strategies.

Artiva Biotherapeutics' CEO Fred Aslan, MD, explains the strategic advantages of pursuing both a company-sponsored trial and an investigator-initiated trial simultaneously.

Artiva Biotherapeutics, Inc.’s ARTV share price has surged by 11.11%, which has investors questioning if this is right time ...

Rarely, minocycline can cause hypersensitivity, drug-induced lupus erythematosus ... is approved for the treatment of acne vulgaris (and rosacea). Both nicotinamide and zinc oxide have anti ...

(NASDAQ:ARGX – Free Report) had its price target increased by Guggenheim from $775.00 to $1,100.00 in a report released on Monday morning,Benzinga reports. They currently have a buy rating on the ...

After hours: March 10 at 4:05:04 PM EDT Loading Chart for ARTV ...

Oxytetracycline 500 b.i.d. Inexpensive Take 30 min before food and not with milk Moderate Onycholysis Photosensitivity Benign intracranial hypertension Erythromycin 500 b.i.d. Inexpensive Take on ...

After hours: March 12 at 7:42:43 PM EDT Loading Chart for CABA ...